Division of Shoulder and Elbow Surgery (E.S.P. and A.G.), Department of Orthopedic Surgery (S.S.J. and S.F.D.), Warren Alpert Medical School of Brown University, Providence, Rhode Island.
J Bone Joint Surg Am. 2019 Sep 4;101(17):1593-1600. doi: 10.2106/JBJS.19.00017.
Health-related quality-of-life (HRQoL) scores are required for cost-effectiveness and health-care value analysis. We evaluated HRQoL scores and patient-reported outcome measures (PROMs) in patients with advanced glenohumeral osteoarthritis treated with anatomic total shoulder arthroplasty to establish values of HRQoL scores that can be used for cost-effectiveness and value analysis and to assess relationships between HRQoL scores and shoulder and upper-extremity PROMs.
We analyzed 145 patients (145 shoulders) with glenohumeral osteoarthritis treated with anatomic total shoulder arthroplasty; 93 patients had 1-year follow-up. Preoperative and postoperative functional outcomes were assessed with the Disabilities of the Arm, Shoulder and Hand (DASH) score, the American Shoulder and Elbow Surgeons (ASES) score, the Simple Shoulder Test (SST), and a visual analog scale (VAS) for shoulder pain and function. Health utility was assessed with the EuroQol-5 Dimensions (EQ-5D), Short Form-6 Dimensions (SF-6D), and VAS Quality of Life (VAS QoL). HRQoL score validity was determined through correlations between the PROMs and HRQoL scores. The responsiveness of HRQoL scores was measured through the effect size and the standardized response mean.
There were significant improvements in all PROMs and HRQoL scores (p < 0.001) at 1 year after the surgical procedure. The changes in VAS QoL and EQ-5D were significantly correlated (weak to moderate) with the changes in all PROMs except the SST, demonstrating comparably acceptable validity. The VAS QoL had a large effect size (1.833) and standardized response mean (1.603), and the EQ-5D also had a large effect size (1.163) and standardized response mean (1.228), demonstrating responsiveness. The effect sizes of all PROMs were larger than those of the HRQoL scores. The change in SF-6D had only a moderate effect size and standardized response mean and was not significantly correlated with the change in any of the PROMs.
PROMs and HRQoL scores are not interchangeable, and studies of the cost-effectiveness and value of shoulder arthroplasty should incorporate both shoulder and upper-extremity PROMs and HRQoL scores. The findings of this study provide data on HRQoL scores that are specific to the treatment of advanced glenohumeral osteoarthritis with anatomic total shoulder replacement and can be used for future cost-effectiveness and value analysis studies.
Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.
健康相关生活质量(HRQoL)评分是成本效益和医疗保健价值分析所必需的。我们评估了接受解剖全肩关节置换术治疗的晚期肩关节炎患者的 HRQoL 评分和患者报告的结果测量(PROMs),以确定可用于成本效益和价值分析的 HRQoL 评分值,并评估 HRQoL 评分与肩部和上肢 PROMs 之间的关系。
我们分析了 145 例(145 肩)接受解剖全肩关节置换术治疗的肩关节炎患者;93 例患者有 1 年随访。使用上肢残疾问卷(DASH)评分、美国肩肘外科医生(ASES)评分、简易肩部测试(SST)和肩部疼痛和功能的视觉模拟量表(VAS)评估术前和术后功能结果。使用欧洲五维健康量表(EQ-5D)、短格式 6 维度量表(SF-6D)和 VAS 生活质量(VAS QoL)评估健康效用。通过 PROMs 和 HRQoL 评分之间的相关性确定 HRQoL 评分的有效性。通过效应大小和标准化反应均值测量 HRQoL 评分的反应性。
手术后 1 年,所有 PROM 和 HRQoL 评分均有显著改善(p<0.001)。VAS QoL 和 EQ-5D 的变化与所有 PROM (除 SST 外)的变化均呈显著相关性(弱至中度),表明具有相当可接受的有效性。VAS QoL 的效应量较大(1.833),标准化反应均值较大(1.603),EQ-5D 的效应量也较大(1.163),标准化反应均值较大(1.228),反应性较好。所有 PROM 的效应量均大于 HRQoL 评分的效应量。SF-6D 的变化仅具有中等效应量和标准化反应均值,且与任何 PROM 的变化均无显著相关性。
PROMs 和 HRQoL 评分不能互换,肩部关节置换术的成本效益和价值研究应同时纳入肩部和上肢 PROMs 和 HRQoL 评分。本研究的结果提供了特定于解剖全肩关节置换术治疗晚期肩关节炎的 HRQoL 评分数据,可用于未来的成本效益和价值分析研究。
治疗学 IV 级。有关证据水平的完整描述,请参阅作者指南。